Prognostic impact of measurable residual disease in AML patients treated frontline with azacitidine and venetoclax: results from the French VENAURA registry

Leukemia

Real-World Outcomes in NPM1-Mutated Acute Myeloid Leukemia: The Impact of Measurable Residual Disease on Disease Relapse

Am J Hematol

Tsirigotis P, Garofalaki M, Lazana I, Liga M, Gigantes S, Kopsaftopoulou A, Tziotziou E, Roumelioti A, Tsintziloni E, Hatzis S, Konstantellos I, Benetatos L, Barbarousi D, Tzenou T, Asimakopoulos JV, Karagiannidi A, Barakos G, Delimpasi S, Stoumbos D, Stamouli M, Plata E, Valera K, Giannouli S, Chatzidimitriou C, Gkolfinopoulou G, Siakantaris MP, Kotsopoulou M, Voulgarelis M, Chondropoulos S, Zina V, Gkirkas K, Kapsali E, Matsouka C, Vassilakopoulos TP, Spyridonidis A, Angelopoulou M, Baltadakis I

doi: 10.1002/ajh.70322

Leukemia

Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model

Leukemia

Venditti A, Hou JZ, Fenaux P, Jonas BA, Vrhovac R, Montesinos P, Garcia JS, Rizzieri D, Thirman MJ, Zhang M, Potluri J, Miller C, Dhalla M, Pullarkat V

doi: 10.1038/s41375-025-02730-3

Leukemia

Real-world heterogeneity in the prognostic value of pre-transplant flow cytometry measurable residual disease in acute myeloid leukemia in first complete remission: CIBMTR analysis

Haematologica

Tettero JM, Zhang MJ, Liu W, Nawas MT, Milano F, Bejanyan N, Bachanova V, Broglie L, Saber W, Gui G, Dillon LW, Walter RB, Page KM, Hourigan CS, El Chaer F

doi: 10.3324/haematol.2026.300764

Genitourinary Cancer

Prognostic Impact of the AML60+ Score for Elderly Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents: A Retrospective Multicentric Analysis

Cancers (Basel)

Petermichl V, Fuchs S, Weber M, Gobat K, Micheloud C, Graf L, Gerth Y, Goede JS, Lehmann T, Driessen C, Mey UJM, Cathomas R, Cogliatti S, Silzle T

doi: 10.3390/cancers17162658

Multiple Myeloma (MM)

Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial

J Clin Oncol

Jin JX, Ginde VR, Huhn S, Reichert P, Bertsch U, Fenk R, Besemer B, Boquoi A, Schroers R, von Metzler I, Hänel M, Mann C, Leypoldt LB, Heilmeier B, Scheid C, Peters-Regehr T, Blau IW, Müller-Tidow C, Luntz S, Holderried TAW, Trautmann-Grill K, Gezer D, Klaiber-Hakimi M, Müller M, Shumilov E, Knauf W, Michel CS, Geer T, Riesenberg H, Lutz C, Raab MS, Weinhold N, Hoffmann M, Benner A, Findeisen P, Weisel KC, Salwender HJ, Mai EK, Goldschmidt H, German-Speaking Myeloma Multicenter Group (GMMG) HD7 Investigators

doi: 10.1200/JCO-25-02957

Breast Cancer

Chemo-prAIdict Breast: A deep learning solution for predicting residual disease on biopsies of breast cancer patients treated with neoadjuvant chemotherapy

Eur J Cancer

Valderrama NF, Morel LO, Mweze DT, Derangère V, Desmoulins I, Mayeur D, Kaderbhai C, Ilie S, Hennequin A, Roussot N, Bergeron A, Beltjens F, Pescia C, Morel HP, Coutant C, Rittscher J, Arnould L, Vinçon N, Ladoire S

doi: 10.1016/j.ejca.2026.116222

Leukemia

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial

Lancet

Davids MS, Eyre TA, Woyach JA, Roeker LE, Ferrajoli A, Wang Y, Tam CS, Jurczak W, Zinzani PL, Šimkovič M, Li JY, Bosch F, Roos-Weil D, Cramer P, Osterborg A, Islam P, Jacobs R, Skarbnik A, Bhat SA, Kang S, Chen M, Nguyen B, McNeely SC, Chung KL, Oliveira JM, Ito R, Ghia P, Wierda WG

doi: 10.1016/S0140-6736(26)01204-3

ASH 2025

Lymphoma

Prognostic value of early MRD status in LBCL patients treated with axi-cel or liso-cel

EHA 2026

Leukemia

Related content

Real-World Outcomes in NPM1-Mutated Acute Myeloid Leukemia: The Impact of Measurable Residual Disease on Disease Relapse

Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model

Real-world heterogeneity in the prognostic value of pre-transplant flow cytometry measurable residual disease in acute myeloid leukemia in first complete remission: CIBMTR analysis

Prognostic Impact of the AML60+ Score for Elderly Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents: A Retrospective Multicentric Analysis

Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial

Chemo-prAIdict Breast: A deep learning solution for predicting residual disease on biopsies of breast cancer patients treated with neoadjuvant chemotherapy

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial

Prognostic value of early MRD status in LBCL patients treated with axi-cel or liso-cel

CLL13/GAIA: Final 5-year analysis identifies NOTCH1 and EGR2 mutations as independent prognostic factors in venetoclax-treated CLL